Evidence map›Paper›PMID 30538953›Full record

ArticleFrontiers in oncology2018

Interactions Between

Monika Bokori-Brown, Jeremy Metz, Peter G Petrov, Francis Mussai, Carmela De Santo, Neil J Smart, Sarah Saunders, Bridget Knight, Ira Pastan, Richard W Titball and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Monika Bokori-BrownCollege of Life and Environmental Sciences, School of Biosciences, University of Exeter, Exeter, United Kingdom.
Jeremy MetzCollege of Life and Environmental Sciences, School of Biosciences, University of Exeter, Exeter, United Kingdom.
Peter G PetrovCollege of Engineering, Mathematics and Physical Sciences, Department of Physics and Astronomy, University of Exeter, Exeter, United Kingdom.
Francis MussaiInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Carmela De SantoInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Neil J SmartExeter Surgical Health Services Research Unit, Royal Devon and Exeter Hospital, Exeter, United Kingdom.
Sarah SaundersHistopathology Department, Royal Devon and Exeter Hospital, Exeter, United Kingdom.
Bridget KnightNational Institute for Health Research Exeter Clinical Research Facility, Royal Devon and Exeter National Health Service Foundation Trust, Exeter, United Kingdom.
Ira PastanLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States.
Richard W TitballCollege of Life and Environmental Sciences, School of Biosciences, University of Exeter, Exeter, United Kingdom.
C Peter WinloveCollege of Engineering, Mathematics and Physical Sciences, Department of Physics and Astronomy, University of Exeter, Exeter, United Kingdom.
University of Exeter · GBRoyal Devon and Exeter Hospital · GBUniversity of Birmingham · GBCenter for Cancer Research · USNational Institute for Health Research · GB

Funding

Clinical Trials with ImmunotoxinsZIABC010020 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PASTAN, IRA · 2009 to 2022
$11.7M
Cancer Research UK 17973Medical Research Council MC_PC_15054
6 · The paper itself

Abstract

Acute Lymphoblastic Leukemia (ALL) remains the most frequent cause of cancer-related mortality in children and novel therapies are needed for the treatment of relapsed/refractory childhood ALL. One approach is the targeting of ALL blasts with the

Indexed as

cancer treatmentCAT-8015HUSimmunotoxinMoxetumomab pasudotoxpediatric acute lymphoblastic leukemiared blood cellsVLS

Identifiers

PMID30538953
PMCPMC6277520
OpenAlexW2901281162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.